Teva Among Beneficiaries As Bystolic Antitrust Case Dismissed
Agreements In 2012 And 2013 Alleged To Have Delayed Competition Until 2021
Executive Summary
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.
You may also be interested in...
ANI Ready For Full-Scale Commercial Launch Of FDA-Approved Cortrophin Gel
ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. Meanwhile, ANI’s $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently.
Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.
Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.